DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Cristofanilli M, Turner NC, Bondarenko I et al.
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Lancet Oncol 2016;
pii S1470-2045(15)00613-0
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.